Detailed narrative
Generational Growth Drivers and Innovation Pipeline
Medtronic is strategically focusing on four generational growth drivers: the PFA platform for AFib, Symplicity Spyral for hypertension, Altaviva for urinary incontinence, and the Hugo surgical robot. Each product is projected to generate over $1 billion in revenue, targeting large, underpenetrated markets.
The company emphasizes a continuous pipeline of new technologies, developed internally or through M&A, across high-need, high-growth categories such as MMA, carotid stenting, thrombectomy, and cardiac rhythm management, reinforcing a steadily improving growth outlook.
Cardiac Ablation Solutions (CAS) and PFA Momentum
The CAS business continues its strong performance, with 80% year-over-year growth, driven by PFA's nearly 200% worldwide growth. Medtronic gained 4 points of share in the $13+ billion market with its Affera platform and Sphere-9 catheter, which is praised for its versatility, safety, and durability across various procedures.
Future plans include Sphere-9's Japan launch and VT indication submission in H1 CY26, alongside the CE Mark and U.S. pivotal trial for the next-gen Sphere-360 catheter, expected to commercialize in Europe this spring.
Market Development for Symplicity Spyral and Altaviva
Medtronic is actively building new markets for Symplicity Spyral for hypertension and Altaviva for urge urinary incontinence. For Symplicity, direct-to-consumer campaigns have led to a 50x increase in website visits, with over 200 new accounts opened and 100 million covered lives in the U.S.
Altaviva, a simple yet transformative device for 16 million U.S. patients, is seeing strong early interest with over 500 physicians trained. The company is investing in market development, referral pathways, health economics, and brand building for these profitable new segments.
Hugo Robot and Surgical Business Evolution
The Hugo surgical robot received FDA clearance for urologic procedures, marking its purposeful U.S. launch with initial installations and cases already completed at sites like Cleveland Clinic. Hugo's differentiation includes its flexibility, portability, open console, and integration with the Touch Surgery digital ecosystem, which has surpassed 1,000 global installations.
Medtronic plans to expand Hugo into additional U.S. indications, such as hernia, leveraging its full continuum of surgical care offerings across open, laparoscopic, and robotic-assisted surgeries.
Neuroscience Portfolio and Stealth AXiS Advancement
Despite Neuroscience growing below expectations this quarter, the segment is poised for future impact with its broad pipeline. A major milestone was the FDA clearance for the Stealth AXiS Surgical System for spinal procedures. This transformative platform unifies AI-powered planning, robotics, and navigation into a seamless system, designed to integrate with the 70% of U.S. spine procedures that are navigated.
Stealth AXiS is expected to drive share gains, lower barriers to robotics adoption, and extend Medtronic's leadership, with future cranial and ENT indications anticipated.
Diabetes Business Innovation and Strategic Separation
The Diabetes business delivered strong reported and organic growth, driven by double-digit international performance and U.S. acceleration from new launches like Simplera Sync and Instinct. The 780G system received expanded FDA indications and is now available through pharmacy agreements covering most commercially insured lives.
Medtronic also submitted MiniMed Flex to the FDA, initiated the Vivera pivotal study, and plans to submit the MiniMed Fit patch pump by fall. The planned two-step IPO and split of MiniMed remains on track for completion by the end of calendar year 2026.